AbbVie Says Phase 3 Trial of Atogepant for Episodic Migraine Met Primary, Secondary Endpoints


MT Newswires 2023

All news about ABBVIE INC.

Analyst Recommendations on ABBVIE INC.

Sales 2023 52 648 M

Net income 2023 11 591 M

Net Debt 2023 46 740 M

P/E ratio 2023 24,2x
Yield 2023 3,68%
Capitalization 285 B
285 B
EV / Sales 2023 6,31x
EV / Sales 2024 6,21x
Nbr of Employees 50 000
Free-Float 97,4%



Duration :


Period :




AbbVie Inc. Technical Analysis Chart | MarketScreener

Technical analysis trends ABBVIE INC.

Short Term Mid-Term Long Term
Trends Bullish Neutral Neutral

Income Statement Evolution

Sell

Buy

Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 161,74 $
Average target price 164,80 $
Spread / Average Target 1,89%


Read more here: Source link